Media Coverage

Four local students from two academic institutions have been selected to participate in the American Heart Association’s Historically Black Colleges and Universities (HBCU) Scholars program, which is designed to help address racial disparity among medical students and physicians. According to the Association of American Medical Colleges, only eight percent of medical students and five percent of physicians are Black and African American. The program is funded by a grant provided by the Quest Diagnostics Foundation, which also supports the American Heart Association’s Hispanic Serving Institutes (HSI) Scholars Program.

Scipher Medicine and Quest Diagnostics have announced a multiyear collaboration to expand access to diagnostic services for patients with rheumatoid arthritis (RA).

Quest Diagnostics is teaming up with a Spain-based biotech to bring an advanced colorectal cancer screening blood test to the U.S. Under the new partnership, the Secaucus-headquartered testing provider will work with UDX to develop and seek U.S. Food and Drug Administration premarket approval for a novel “liquid biopsy” blood test to screen for colorectal cancer, the third leading cause of cancer death in the country, according to a Nov. 20 announcement.

For its third annual look-ahead, CLP recently asked a wide range of clinical laboratory experts to look into their professional crystal balls and make their predictions for 2024.

In honor of National Alzheimer’s Awareness Month, held November 2023, Michael K. Racke, MD, medical director of neurology at Quest Diagnostics, delved into some commonly-believed myths about Alzheimer disease and provided his insight on the scientific explanations for these assumptions.

Quest Diagnostics recently launched Quest Mobile™, which the Secaucus-based health care company says will make it easier and more convenient for patients to have a specimen collected for lab testing nationwide. Patients can request an appointment for at-home specimen collection with a trained Quest Mobile phlebotomist for a broad range of laboratory tests in the comfort of their home.

Michael McPhaul, MD, is senior medical director of endocrinology at Quest Diagnostics and editor of the Journal of Investigative Medicine High Impact Case Reports. His work at Quest Diagnostics focuses on the development of new tests for biomarkers of metabolic health to improve prevention, early diagnosis, and monitoring for patients with cardiometabolic health conditions. Here, he discusses advances in insulin resistance testing.

Alzheimer's disease is the most common form of dementia and affecting about 6 million people in the United States. A simple blood test is providing a new way for doctors to detect the potential risk of Alzheimer's disease in its early stages. Here to talk about this groundbreaking new approach is a board-certified neurologist and medical director of neurology at Quest Diagnostics.

Diagnostics firm Diadem said Wednesday that it has licensed exclusive US rights to its AlzoSure Predict Alzheimer's blood test to Quest Diagnostics. Under the agreement, Quest can develop, validate, and market the assay, which is intended to identify individuals likely to progress to Alzheimer's disease, as a laboratory-developed test in the US. AlzoSure Predict measures a variant of the p53 protein that has been linked to Alzheimer's disease.

Laboratory operator Quest Diagnostics on Tuesday raised its full-year sales forecast after beating third-quarter expectations for revenue and profit, buoyed by a recovery in routine testing. The company raised its full-year net sales forecast to $9.19 billion to $9.24 billion, from its previous expectations of $9.12 billion to $9.22 billion. Sales from Quest's base business, which includes a range of diagnostic tests for allergies, chronic diseases and cancer, rose 4.6% to $2.27 billion in the third quarter. That extends a rebound in routine health check-ups delayed due to pandemic-related lockdowns for diagnostic firms like Quest and eases the blow from plunging demand for COVID-19 tests.